Clinical trials: Skin Tests
Allergy Skin, Allergy
NeoMatriX Wound Matrix Collagen Dressing Skin Prick Test
The objective of this study is to investigate the potential of NeoMatriXTM Wound Matrix to cause an allergic response to healthy volunteers using a skin prick test.
- Conditions
- Allergy Skin, Allergy, Dermatitis, Allergic Contact
- Trial name
- NCT03522675
- Testing
- NeoMatriX Wound MatriX Collagen Dressing
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- NeXtGen Biologics, Inc.
Palmoplantar Pustulosis (PPP)
A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis
The primary objective is to provide dose-ranging data for 4 dose regimens of BI 655130 compared to placebo on the primary endpoint of percentage change from baseline in PPP ASI at Week 16.
- Trial name
- NCT04015518
- Testing
- Spesolimab
- Where
- 88 sites in United States, Australia and 13 more
- Volunteers
- 152 people
- Sponsor
- Boehringer Ingelheim
Neoplasms, Breast Neoplasms
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
This is a study in adult patients with different types of cancer. The purpose of this study is to find a safe dose of: Xentuzumab in combination with abemaciclib Xentuzumab in combination with abemaciclib and hormonal therapies…
- Trial name
- NCT03099174
- Testing
- Xentuzumab, Abemaciclib, Letrozole
- Where
- 30 sites in United States, Denmark and 5 more
- Volunteers
- 133 people
- Sponsor
- Boehringer Ingelheim
Contact Dermatitis
DermAI to Evaluate Human Factor of Testing
The purpose of this research is to improve how well remote patch allergy testing works and make sure they are easy and practical for people to use from home.
- Trial name
- NCT06387472
- Testing
- AI algorithm to evaluate photographs of skin test patch regions, Allergen Patch
- Where
- United States
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Generalized Pustular Psoriasis
A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis
This is a study in adolescents and adults with Generalized Pustular Psoriasis (GPP). People between 12 and 75 years old can take part in the study.
- Trial name
- NCT04399837
- Testing
- Spesolimab
- Where
- 72 sites in United States, Argentina and 21 more
- Volunteers
- 123 people
- Sponsor
- Boehringer Ingelheim
Eczema
Test to Determine the Effectiveness of Moisturizing Balm Used on Babies With Dry, Itchy Skin
The purpose of this 3 week study is to test the effectiveness of an over-the-counter (OTC) skin balm in infants and toddlers with mild to moderate dry, itchy skin.
- Trial name
- NCT02404493
- Testing
- EpiCeram Skin Barrier Emulsion, 1% Colloidal Oatmeal Balm
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Antifungal Agents
Bioequivalence (BE) Study of Test Griseofulvin 500 Milligram (mg) Tablets Versus Reference and Dose Proportionality Study of Test Griseofulvin 250 mg and 500 mg Tablets Under Fed Conditions
Griseofulvin is an antifungal agent used in treatment of Dermatophytosis caused by Microsporum spp. (species), Trichophyton spp., Epidermophyton spp., where topical therapy is considered inappropriate or has failed.
- Trial name
- NCT04318535
- Testing
- Griseofulvin 500 mg, Griseofulvin 250 mg, Reference Griseofulvin 500 mg
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Contact Dermatitis
Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response
We propose a prospective, multi-center, double-blind, randomized study comparing the diagnostic performance (primary) and safety (secondary) of 3 concentrations of Disperse blue 106 and 4 concentrations of Bronopol in 40 adult…
- Trial name
- NCT00640250
- Testing
- T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens
- Where
- 2 sites in United States, Denmark
- Volunteers
- 48 people
- Sponsor
- Allerderm
Breast Cancer
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
This trial will evaluate the clinical significance of the PRO Onc assay and will assess the efficacy of HER2-targeted therapy in patients with HER2-negative breast cancer who have been identified as having HER2…
- Trial name
- NCT01048099
- Testing
- PRO Onc Assay and Treatment, Trastuzumab, Pertuzumab
- Where
- 7 sites in United States
- Volunteers
- 283 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Carcinoma
Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy
This phase III trial studies how well Mepitel Film works in reducing radiation dermatitis (redness and peeling) in patients with breast cancer during radiation therapy after a mastectomy.
- Trial name
- NCT04989504
- Testing
- Best Practice, Wound Dressing Material, Quality-of-Life Assessment
- Where
- 49 sites in United States
- Volunteers
- 216 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Neoplasms, Breast Cancer
Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing
Background: Human epidermal growth factor receptor 2 (HER2, also known as c-erbB2 or neu)/neu (HER2) is a tumor protein that appears in almost a third of breast cancers and in several other types of cancers such as colon…
- Conditions
- Breast Neoplasms, Breast Cancer, Adenocarcinomas, Metastatic Solid Tumors Characterized by HER2/Neu Expression
- Trial name
- NCT01730118
- Testing
- Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer
RATIONALE: Analyzing genes for changes before and after chemotherapy may help doctors predict a patient's response to treatment and help plan the most effective treatment.
- Trial name
- NCT00088829
- Testing
- paclitaxel, microarray analysis, biopsy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Georgetown University
Bacteria Microflora Reduction
Pilot Evaluation of Two Test Materials With a Positive Control When Used as a Patient Preoperative Skin Preparation
Comparative Study of Antimicrobial Effectiveness Evaluation of 26ml Project X, 5.1ml Project X and Prevantics Maxi Swabstick following ASTM E1173 - Standard Test Method for Evaluation of Preoperative, Precatheterization, or…
- Trial name
- NCT03861780
- Testing
- Project X 26ml, Project X 5.1ml, Prevantics Maxi Swabstick
- Where
- United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Professional Disposables International, Inc.
Erythema, Edema
Repeated Insult Patch Test of Personal Lubricants
Determine the ability of the study material (personal lubricant) to cause sensitization by repeated topical application to the skin of humans under controlled patch test conditions.
- Trial name
- NCT02297841
- Testing
- Experimental: Novel lubricant Miami Fragrance, Experimental: Novel lubricant Miami no Fragrance, KY Liquid lubricant
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- Church & Dwight Company, Inc.
Melanoma
A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma
The objective of this study is to evaluate the clinical activity of the GSK2132231A immunotherapeutic in patients with MAGE-A3 positive unresectable metastatic melanoma presenting with the predictive gene signature.
- Trial name
- PREDICT (NCT00942162)
- Testing
- Immunotherapeutic GSK2132231A
- Where
- 63 sites in United States, France and 6 more
- Volunteers
- 125 people
- Sponsor
- GlaxoSmithKline
Herpes Simplex
Clinical Evaluation of the Sentosa SA HSV1/2 Qualitative PCR Test
The purpose of this study is to evaluate the performance of the Sentosa SA HSV1/2 Qualitative PCR Test. Precision of results and concordance of results with a reference assay will be evaluated.
- Trial name
- NCT02685956
- Testing
- Vela Sentosa SA HSV1/2 Qualitative PCR Test
- Where
- 9 sites in United States
- Volunteers
- 2,295 people
- Sponsor
- Vela Diagnostics
CHRONIC SPONTANEOUS URTICARIA
Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment
Evaluate the proportion of patients with an urticaria control test [UCT] score of greater than or equal to 12 at Week 12.
- Trial name
- SUNRISE (NCT02550106)
- Testing
- OMALIZUMAB
- Where
- 29 sites in France
- Volunteers
- 136 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
A Single Arm Pilot Study to Refine a Novel Approach to Exercise Promotion Based on Affect-regulation
The purpose of this study is to refine the use of an affect-regulated exercise prescription for use with survivors of breast cancer.
- Trial name
- NCT04903249
- Testing
- Core Exercise Promotion Intervention
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Skin Angiosarcoma, Skin Radiation-Related Angiosarcoma
Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma
This phase II trial studies how well paclitaxel with and without nivolumab works in treating patients with soft tissue sarcoma that have not received taxane drugs, and how well nivolumab and cabozantinib work in treating taxane…
- Conditions
- Skin Angiosarcoma, Skin Radiation-Related Angiosarcoma, Visceral Angiosarcoma
- Trial name
- NCT04339738
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 171 sites in United States, Guam
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Breast Adenocarcinoma, Hormone Receptor Positive
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
This randomized phase III trial studies the best individual therapy for women who have node-negative, estrogen-receptor positive breast cancer by using a special test (Oncotype DX), and whether hormone therapy alone or hormone…
- Conditions
- Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7
- Trial name
- TAILORx (NCT00310180)
- Testing
- Anastrozole, Exemestane, Laboratory Biomarker Analysis
- Where
- 1,222 sites in United States, Australia and 6 more
- Volunteers
- 10,273 people
- Sponsor
- National Cancer Institute (NCI)